Product Details
Product Name:
LQZ-7I |
CAS No.:
195822-23-2 |
Purity:
99.9% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | LQZ-7I |
Description | LQZ-7I is an inhibitor of surviving-targeting. It orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 120 mg/mL (344.48 mM), Sonication is recommended.
|
Keywords | LQZ-7I | LQZ7I | inhibit | Survivin | LQZ 7I | Inhibitor | tumor | dimerization |
Inhibitors Related | Sepantronium bromide | Cucurbitacin IIA | GDP366 | FL118 | Shepherdin 79-87 acetate | LQZ-7F |
Related Compound Libraries | Apoptosis Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Angiogenesis related Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2919019-72-8
$159.00 / 1mg
-
CAS:354543-09-2
$195.00 / 1mg
-
CAS:1353979-43-7
$39.00 / 5mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |